1. Evolution After Anti‐TNF Discontinuation in Patients With Inflammatory Bowel Disease: A Multicenter Long‐Term Follow‐Up Study. (January 2017) Authors: Casanova, M J; Chaparro, M; García‐Sánchez, V; Nantes, O; Leo, E; Rojas‐Feria, M; Jauregui‐Amezaga, A; García‐López, S; Huguet, J M; Arguelles‐Arias, F; Aicart, M; Marín‐Jiménez, I; Gómez‐García, M; Muñoz, F; Esteve, M; Bujanda, L; Cortés, X; Tosca, J; Pineda, J R; Mañosa, M Journal: American journal of gastroenterology Issue: Volume 112:Number 1(2017) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P437 Risk of immunomediated adverse events or secondary loss of response to infliximab in elderly patients with inflammatory bowel disease: a cohort study of the ENEIDA registry. (25th January 2019) Authors: Calafat, M; Mañosa, M; Panes, J; Nos, P; Iglesias, E; Vera, I; López-Sanromán, A; Guardiola, J; Taxonera, C; Mínguez, M; Martín, M D; de Castro, L; Riestra, S; Rivero, M; García-Planella, E; Calvet, X; García-López, S; Andreu, M; Gomollón, F; Barrio, J Journal: Journal of Crohn's and colitis Issue: Volume 13(2019)Supplement 1 Page Start: S328 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗